Stance Capital LLC Acquires 36,272 Shares of Edwards Lifesciences Corporation $EW

Stance Capital LLC boosted its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 373.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 45,994 shares of the medical research company’s stock after buying an additional 36,272 shares during the quarter. Edwards Lifesciences makes up approximately 1.3% of Stance Capital LLC’s portfolio, making the stock its 18th biggest position. Stance Capital LLC’s holdings in Edwards Lifesciences were worth $3,577,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Norges Bank acquired a new position in shares of Edwards Lifesciences in the 2nd quarter valued at about $580,640,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its stake in Edwards Lifesciences by 111.2% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock worth $714,006,000 after purchasing an additional 4,805,819 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Edwards Lifesciences by 278.3% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after purchasing an additional 4,108,270 shares during the period. Marshall Wace LLP increased its holdings in Edwards Lifesciences by 127.5% in the second quarter. Marshall Wace LLP now owns 6,895,579 shares of the medical research company’s stock worth $539,303,000 after purchasing an additional 3,864,908 shares in the last quarter. Finally, Viking Global Investors LP bought a new stake in Edwards Lifesciences in the third quarter worth approximately $238,688,000. Institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $85.38, for a total transaction of $87,002.22. Following the completion of the sale, the vice president directly owned 33,934 shares of the company’s stock, valued at approximately $2,897,284.92. The trade was a 2.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $84.92, for a total value of $1,103,960.00. Following the completion of the sale, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at approximately $3,371,239.08. This trade represents a 24.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 61,718 shares of company stock worth $5,236,281 in the last quarter. Insiders own 0.34% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on EW shares. The Goldman Sachs Group reiterated a “buy” rating and issued a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Robert W. Baird set a $90.00 price target on shares of Edwards Lifesciences in a report on Monday, January 12th. Wells Fargo & Company lifted their price target on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. Evercore reiterated an “outperform” rating and set a $94.00 price objective on shares of Edwards Lifesciences in a report on Monday, January 5th. Finally, TD Cowen raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Friday, January 9th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $96.14.

Edwards Lifesciences Stock Performance

NYSE EW opened at $84.24 on Wednesday. The company has a market cap of $48.93 billion, a P/E ratio of 46.03, a PEG ratio of 2.18 and a beta of 0.93. The company has a fifty day simple moving average of $82.36 and a 200 day simple moving average of $81.62. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.89.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The business had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.54 billion. During the same quarter in the previous year, the company posted $0.59 EPS. The business’s quarterly revenue was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Sell-side analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.